Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real-World Study.
4 affiliations
- 14th Department of Internal Medicine - Hematology, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
- 2Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
- 3Tissue Bank, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
- 4Department of Clinical Pharmacy, Hospital Pharmacy, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
Abstract
Background
Obinutuzumab-based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion-related reactions (IRRs) and prolonged administration increase patient burden and outpatient chair occupancy. Evidence on shortened obinutuzumab infusion in CLL remains limited.Aims
To evaluate the safety, feasibility, and clinical outcomes of a 2-h obinutuzumab infusion protocol in treatment-naïve CLL.Methods
This retrospective single-center cohort study included 112 treatment-naïve patients receiving venetoclax-obinutuzumab (n = 72) or obinutuzumab-chlorambucil (n = 40). From cycle 1 day 8 onward, patients were managed according to either a shortened-infusion strategy (Short; n = 64) or a standard-duration strategy (Long; n = 48). The primary outcome was IRR incidence and severity; secondary outcomes included chair time, response rate, and progression-free survival.Results
IRR rates did not differ significantly between the Short and Long groups (71.9% vs. 83.3%; odds ratio, 0.51; 95% confidence interval, 0.17-1.41; p = 0.18). Most IRRs occurred during the first infusion (87.4%), before implementation of the shortened protocol. Because cycle 1 day 1 and day 2 were administered using the same standard protocol in both groups, the safety comparison relevant to the shortened-infusion strategy begins at cycle 1 day 8; IRRs were infrequent from cycle 1 day 8 onward, and none occurred from cycle 1 day 15 onward, when eligible patients in the Short group were receiving the 2-h infusion. Grade 2 reactions predominated (91.6%); no Grade 4 IRRs occurred among the 112 patients included in the analysis. The shortened protocol saved 1.8 h per visit and 11.2 h per patient (42%). No apparent adverse signal in response or progression-free survival was observed.Conclusions
In frontline CLL care, a 2-h obinutuzumab infusion from cycle 1 day 8 was feasible, safe, and substantially reduced chair time, supporting its use to improve outpatient treatment efficiency.
Related
- Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage
- Kinetic BCR::ABL1 reduction by transcript types in frontline CML treatment: a GIMEMA LabNet CML network survey
- Baseline radiographic and microbiologic predictors of treatment outcomes in a shortened all-oral regimen for MDR/RR-TB
- Ketamine Infusion Protocol for the Treatment of Complex Regional Pain Syndrome
- Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy
BibTeX
@article{ecsiova2026shortened,
title = {{Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real-World Study.}},
author = {Dominika Écsiová and Eva Vejražková and Pavel Vodárek and Petra Rozsívalová and Lukáš Smolej and Pavel Žák and Martin Šimkovič},
journal = {Cancer medicine},
year = {2026},
month = nov,
doi = {10.1002/cam4.72409},
url = {https://europepmc.org/article/MED/42968440},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real-World Study.
AU - Dominika Écsiová
AU - Eva Vejražková
AU - Pavel Vodárek
AU - Petra Rozsívalová
AU - Lukáš Smolej
AU - Pavel Žák
AU - Martin Šimkovič
PY - 2026
DA - 2026/11/01
JO - Cancer medicine
DO - 10.1002/cam4.72409
UR - https://europepmc.org/article/MED/42968440
AB - Background Obinutuzumab-based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion-related reactions (IRRs) and prolonged administration increase patient burden and outpatient chair occupancy. Evidence on shortened obinutuzumab infusion in CLL remains limited.Aims To evaluate the safety, feasibility, and clinical outcomes of a 2-h obinutuzumab infusion protocol in treatment-naïve CLL.Methods This retrospective single-center cohort study included 112 treatment-naïve patients receiving venetoclax-obinutuzumab (n = 72) or obinutuzumab-chlorambucil (n = 40). From cycle 1 day 8 onward, patients were managed according to either a shortened-infusion strategy (Short; n = 64) or a standard-duration strategy (Long; n = 48). The primary outcome was IRR incidence and severity; secondary outcomes included chair time, response rate, and progression-free survival.Results IRR rates did not differ significantly between the Short and Long groups (71.9% vs. 83.3%; odds ratio, 0.51; 95% confidence interval, 0.17-1.41; p = 0.18). Most IRRs occurred during the first infusion (87.4%), before implementation of the shortened protocol. Because cycle 1 day 1 and day 2 were administered using the same standard protocol in both groups, the safety comparison relevant to the shortened-infusion strategy begins at cycle 1 day 8; IRRs were infrequent from cycle 1 day 8 onward, and none occurred from cycle 1 day 15 onward, when eligible patients in the Short group were receiving the 2-h infusion. Grade 2 reactions predominated (91.6%); no Grade 4 IRRs occurred among the 112 patients included in the analysis. The shortened protocol saved 1.8 h per visit and 11.2 h per patient (42%). No apparent adverse signal in response or progression-free survival was observed.Conclusions In frontline CLL care, a 2-h obinutuzumab infusion from cycle 1 day 8 was feasible, safe, and substantially reduced chair time, supporting its use to improve outpatient treatment efficiency.
SN - 2045-7634
ER -